--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ABSI20260918C9
Medical service
Absci Corporation was incorporated as a limited liability company in Oregon in August 2011. The company is a clinical-stage biopharmaceutical company that develops differentiated antibody therapies using artificial intelligence native methods. Its lead drug candidate, ABS-201, is an anti-prolactin receptor antibody that is being developed for androgenic alopecia and endometriosis, and related clinical trials are ongoing and planned.
